Abstract: The current invention relates to the use of antibodies which bind to VEGF and ANG2 for the treatment of ophthalmologic diseases.

Abstract: The invention relates to a polymer (P) comprising at least one segment (S1) and at least one segment (S2) covalently linked to each other, wherein i) at least one segment (S1) has a number average molecular weight in the range of 6,000-25,000 g/mol and consists of ether repeating units, and for at least 75% by weight of repeating units of the formula —[CH2—CH2—O—]—, ii) at least one segment (S2) has a number average molecular weight of at most 10,000 g/mol and consists of ether repeating units, and for at most 25% by weight of repeating units of the formula —[CH2—CH2—O—]—, iii) polymer (P) comprises terminal groups comprising at least one of hydroxyl, primary amine or salts thereof, secondary amine or salts thereof, carboxylic acid or salts thereof.

Abstract: The current invention relates to antibodies which bind to VEGF and ANG2 for use in the treatment of ocular vascular diseases such as neovascular AMD (nAMD) (also known as choroidal neovascularization [CNV] secondary to age-related macular degeneration [AMD] or wet AMD), diabetic retinopathy in particular diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion (RVO).

Abstract: Systems, methods, and computer readable media are disclosed for generating, modifying, and using machine learning models to predict and evaluate variances between data sets. Methods disclosed herein may include identifying features that characterize members of a data set, generating a machine learning model using identified features, using the machine learning model and the group to assign feature attributions to the features, and predicting the impact of those features on behaviors of the first data set and a second data set.

Abstract: The current invention relates to the use of antibodies which bind to VEGF and ANG2 for the treatment of ophthalmologic diseases.

Abstract: Provided are methods for treating an ocular neovascular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and flanked by AAV2 inverted terminal repeats (ITRs), and b) an AAV2 capsid protein comprising an amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to an AAV2 VP1 capsid protein.

Abstract: A surgical aiming system is disclosed comprising a one or more fixation plates, an aiming assembly, a one or more nails and a plurality of screws. Said aiming assembly comprising a channeling assembly and a plurality of channels. Said one or more fixation plates comprising a plurality of plate apertures capable of receiving a portion of said plurality of screws. Said plurality of channels in said aiming assembly are capable of aligning a portion of said plurality of screws with said plurality of plate apertures in a first fixation plate. Said plurality of channels receive and align said plurality of screws as they are secured to said first bone. Said first fixation plate being extramedullary attached to a portion of said surface of said first bone; and said plurality of channels of said aiming assembly being aligned to identify a one or more intramedullary locations within said first bone.

Abstract: Patients with polypoidal choroidal vasculopathy receive a combination of both (i) a photodynamic therapy, such as verteporfin and (ii) a non-antibody VEGF antagonist.

Abstract: The present invention relates to the use of a non-antibody VEGF antagonist, in the treatment of choroidal neovascularisation secondary to diseases other than age-related macular degeneration and pathologic myopia.

Abstract: A surgical aiming system is disclosed comprising a one or more fixation plates, an aiming assembly, a one or more nails and a plurality of screws. Said aiming assembly comprising a channeling assembly and a plurality of channels. Said one or more fixation plates comprising a plurality of plate apertures capable of receiving a portion of said plurality of screws. Said plurality of channels in said aiming assembly are capable of aligning a portion of said plurality of screws with said plurality of plate apertures in a first fixation plate. Said plurality of channels receive and align said plurality of screws as they are secured to said first bone. Said first fixation plate being extramedullary attached to a portion of said surface of said first bone; and said plurality of channels of said aiming assembly being aligned to identify a one or more intramedullary locations within said first bone.

Abstract: A surgical aiming system is disclosed comprising a one or more fixation plates, an aiming assembly, a one or more nails and a plurality of screws. Said aiming assembly comprising a channeling assembly and a plurality of channels. Said one or more fixation plates comprising a plurality of plate apertures capable of receiving a portion of said plurality of screws. Said plurality of channels in said aiming assembly are capable of aligning a portion of said plurality of screws with said plurality of plate apertures in a first fixation plate. Said plurality of channels receive and align said plurality of screws as they are secured to said first bone. Said first fixation plate being extramedullary attached to a portion of said surface of said first bone; and said plurality of channels of said aiming assembly being aligned to identify a one or more intramedullary locations within said first bone.

Abstract: Oct-1 is shown to be an oncoprotein because of its known role as an activator of the histone H2B gene and the importance of this gene during DNA synthesis. To determine the role of Oct-1 as an oncoprotein, the cell line 5637 (ATCC HTB9) was transfected with the vector pcDNA3 containing full length, antisense Oct-1 cDNA. This cell line is Rb-defective and has been shown to have increased Oct-1 binding activity as compared to Rb reconstituted clones. After transfection, Oct-1 antisense clones were grown and assayed for the loss of oncogenic characteristics as compared to control transformants.

Abstract: A method of identifying genes that can be activated when methylated; as well as proteins that mediate such activation. The method allows identification of HLA-DRA silencing agents expected to be of therapeutic value in the treatment of inflammation associated with HLA-DRA expression.